Sven Engel has over 35 years of experience in clinical drug development and preclinical research. He has strong networks in the biotech and pharmaceutical industries in Germany, Austria, and Switzerland. As the CEO/COO of SynapCon, he provides expertise in clinical operations, project management, and experience with rare diseases and non-interventional studies. He has managed global projects and has extensive experience working with regulatory authorities and negotiating contracts with investigators.